Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

Officials had initially linked 97 cases to a single conference held by Biogen in February in Boston, but a new study tracking viral genomes suggests the number may be as high as 20,000.

Citizen advocates push the pharmaceutical company to examine a compound that has been used to treat certain coronavirus infections in cats.

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.

The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.

The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.